Company: AGTX
Filing Date: 2025-07-16
Form Type: 10-K
Source: 0001477932-25-005077
Chunk: 40

Company: Agentix Corp.
Filing Date: 2025-07-16
Form: 10-K
Item: Item 1
Chunk 40
---
 in R&D consulting costs.

For the year ended March 31, 2025, general and administrative expenses were $69,898 as compared to $346,543 for our year ended March 31, 2024, a decrease of $276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prior period.

For the year ended March 31, 2025 and 2024, foreign exchange loss was $11,128 and $17,929, respectively.

For the year ended March 31, 2025 and 2024, interest expense, net was $42,669 and $21,034, respectively. The net increase in interest expense related to our increase in loan activity during the year ended March 31, 2025 as compared to our year ended March 31, 2024.

For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.

For the year ended March 31, 2025, cash used from our operating activities was $125,078 of cash as compared to a use of cash of $110,429 during the year ended March 31, 2024.

For the year ended March 31, 2025, cash from financing was $100,00 versus $93,000 for our year ended March 31, 2024. Cash from financings during the year ended March 31, 2025 consisted of $100,000 from loan proceeds received. Cash from financings during the year ended March 31, 2024 consisted of $163,000 from loan proceeds received offset by our payment of $70,000 on our loans.

We did not incur or obtain cash from investing activities during our year ended March 31, 2025 and 2024, respectively.

Liquidity and Capital Resources

Our consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in our consolidated financial statements for the year ended March 31, 2025, we had an accumulated deficit, we did not incur any revenue and we had a